Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

7 Jun 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB

Delamanid (OPC-67683)

This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.

25 May 2012

TB R&D Weekly Update: Expanding Our Options for TB Treatment

tb-e1332174457196

For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.

1 May 2012
by Working Group

Posted in Announcements, Events, TB News

Watch Video from the World TB Day Congressional Briefing

congress-hearing

A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Links to video included.

11 Apr 2012

TB R&D Update: Strategies for Early and Late Stage Drug Development

9.cover

This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing. Additional links to TB R&D publications and news are included.

29 Mar 2012
by Working Group

Posted in Announcements, TB Drug Development, TB News

Working Group on New TB Drugs Launches Strategic Plan 2011-2015

Click here to access publication.

The WGND Strategic Plan 2011-2015 is an update of the “New Drugs” section of the Global Plan to Stop TB: 2011-2015. It describes the progress, gaps, and vision of the WGND and the TB drug development field as a whole.

27 Mar 2012

TB R&D Update: 243rd American Chemistry Society Conference

acs-logo

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB. Additional links to TB R&D News are included.

23 Feb 2012

TB R&D Weekly Update: CSU Identifies Anti-TB Compound against Unique Target

ncb feb2012

This week’s article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–that inhibits an essential cell function of the mycobacteria. Additional links to TB R&D News are included.

20 Jan 2012

TB R&D Weekly Update: TDR Tuberculosis Strain Bank

TDR strain bank

This week we highlight an article looking at the TDR Tuberculosis Strain Bank and its utility. Additional links to TB R&D news are included.

TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay

avgayweb111380

This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research. Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. Additional TB R&D news links are included.

8 Dec 2011
by Heather_Ignatius

Posted in Action, Announcements, Front Lines of TB R&D, TB News

4th Annual G-FINDER Survey Released

gfinderjpg

Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients–donors must commit to taking them across the finish line.